Laddar populära aktier...
Beijer Alma överträffade Analysguidens förväntningar med en tillväxt som både var organisk och förvä...
Softer Q1 than expected, but with solid progress for Private We cut '24e-'26e EBIT by 22-6% on lower...
Förvaltningsresultat sjönk med drygt 6% på årsbasis drivet av en högre genomsnittlig räntenivå.
Snow removal supports strong Q1 (7% EBITA growth) '24e-'26e adj.
Q-linea has secured a US FDA approval, which is positive.
Redeye has updated its estimates for Carasent following the Q1 2024 report, which was more or less i...
Redeye returns with an updated view on Nanologica following its Q1 report.
Q1(24) i korthet Nettoomsättningen under Q1(24) uppgick till 9 mkr (13) och rörelseresultatet uppgic...
Q2 visar operativ styrka och hög aktivitet Hyresintäkterna ökade med 7% till 168 mkr (154) samtidigt...
Doro delivered a soft topline growth but a large part of the softness was due to one-offs.
Full-year revenue and EBIDA guidance from the company remains intact but we lower our 2024 EBITDA fo...
Carlsquare Equity Research presenterar sina första intryck av Enrads kv1 2024-rapport.
Redeye raises its Base Case and forecasts somewhat following a solid Q1 report, beating our expectat...
Adj. EBITA in line, we expect higher margins ahead Minor revisions: adj.
Highest order intake in company's history We lift '24e-'26e EBIT by 14% on higher sales and GMs EBIT...